This inventor holds 1 USPTO granted patent. Top assignee: Xenothera. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Bernard Vanhove: Innovator in Cancer Treatment
Introduction
Bernard Vanhove is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic antibodies.
Latest Patents
Vanhove holds a patent for the "Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer." This invention relates to a combination of non-human mammal polyclonal antibodies directed against cancer cells, along with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies. The patent aims to provide a method for preventing and/or treating cancer in mammal patients.
Career Highlights
Bernard Vanhove is currently associated with Xenothera, a company focused on developing innovative therapies for serious diseases. His work at Xenothera emphasizes the importance of combining different types of antibodies to enhance the effectiveness of cancer treatments.
Collaborations
Vanhove collaborates with Odile Duvaux, contributing to the advancement of research in the field of immunotherapy. Their partnership highlights the collaborative nature of scientific research and the importance of teamwork in achieving breakthroughs.
Conclusion
Bernard Vanhove's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work at Xenothera and collaborations with fellow researchers underscore the significance of innovation in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile